Connective tissue disease associated with interstitial lung disease (CTD-ILD) market is estimated to be $5.9 Billion USD in 2024 and is projected to grow to 9.3 billion, driven by increase in autoimmune Dz, adoption of biologics, ongoing clinical anti-fibrotic trials https://t.co/UqshQgNOau

ILD Begins (8.29.2025) Dr. Jack Cush reviews the news and journal reports from https://t.co/V10S4oVFsv. This week news on vaccines, safety of acetaminophen and more. https://t.co/YlOK3X4hkW https://t.co/9cgcDn0xab

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/Q8mMxtBgZZ

Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/hsUWi27OtQ

Global prevalence of Hidradenitis suppurativa (HS) is 0.99%, but varies globally between 0.67% and 1.46%. HS is assoc w/ female sex. Based on a meta-analysis 22 743 participants, identifying 247 HS pts. https://t.co/TtKdfKiIn3 https://t.co/zOIVUlF5E8

High unemployment in Dutch SLE patients, linked to SLE Sxs & Dz duration. Supervisor support helps with employment. https://t.co/E5jqmUHqo7

Biomarkers in ILD Join Elena K. Joerns, MD, as she highlights key insights on the role of biomarkers in ILD. Sponsored By: Boehringer Ingelheim. https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/tQUvwHD5cX

September is Pulmonary Fibrosis Awareness month. PF & ILD affect more than 250,000 Americans. The Pulmonary Fibrosis Foundation (PFF), will lead a nationwide campaign to raise awareness https://t.co/BYKeLcFP2U https://t.co/746CyLCT0z

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/oAd3JwDR5D

J&J announced it has halted its combination biologic study in difficult to treat RA. Phase 2a DAISY proof-of-concept studied the combo of nipocalimab and TNFi in refractory RA, but 12 wk results failed to evidence of efficacy. https://t.co/T4n4GNqtVC v https://t.co/eSAwrEIYHc

GLP-1 receptor agonists use assoc w/ lower risk of uveitis compared vs controls. EHR study 258 026 ea on GLP-1RA or not. GLP-1RAs exhibited roughly half the risk of developing uveitis. Protective effect greater than that of metformin & insulin but lower than SGLT2i https://t.co/w311b6swc3

ACR Urges Alaska and Montana to Strengthen Rheumatology Care The American College of Rheumatology (ACR) is calling on Alaska and Montana to seize the opportunity to address critical gaps in rheumatology care by accessing funding from the Rural Health Transformation Program https://t.co/exHRCORcCG